Eli Lilly Shares Rally 56.9%, Adding $400B to $1.063T Valuation
LLY•Eli Lilly’s shares climbed 56.86% from $773.86 to $1,213.91 over the past year, adding roughly $400 billion in market value. That rally pushed the company’s market capitalization to $1.063 trillion, eclipsing the $1 trillion threshold and marking a new sector milestone.
1. Year-Long Share Rally
Over the 12 months ending July 2, 2026, Eli Lilly’s stock advanced from $773.86 to $1,213.91 per share, representing a 56.86% increase that outpaced most large-cap healthcare peers. Robust demand for its leading diabetes and obesity franchises underpinned the sustained momentum.
2. Market Capitalization Milestone
The share gain translated into an approximate $400 billion jump in market value, elevating Eli Lilly’s market capitalization to $1.063 trillion. That positions the company among a select group of pharmaceutical firms exceeding the trillion-dollar mark.
3. Impact on Big Pharma Landscape
Surpassing the $1 trillion barrier reshapes competitive dynamics in the drug sector, pressuring peers to demonstrate similar growth drivers. Investor confidence in Lilly’s late-stage pipeline and pricing power has set a new benchmark for valuation across the industry.
